Peer-reviewed veterinary case report
Improving oral GS-441524 treatment for feline infectious peritonitis
By Lee, Sang-Rae et al.·Published in International journal of pharmaceutics·2025·College of Pharmacy, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A dual-strategy approach to improve GS-441524 therapy in feline infectious peritonitis: salt engineering and orally disintegrating tablet development.
- Species:
- cat
Plain-English summary
A cat with feline infectious peritonitis (FIP), a serious and often fatal disease, was treated with a new form of a medication called GS-441524. Researchers developed a salt version of this drug that was much easier for cats to absorb and created a special orally disintegrating tablet that dissolves quickly in the mouth. This new tablet made it simpler to give the medication to cats, ensuring they received the right dose without the usual difficulties of oral administration. The new treatment showed promise in improving the effectiveness of FIP therapy, making it a more practical option for cat owners.
People also search for: cat FIP treatment · GS-441524 for cats · feline infectious peritonitis medication
Abstract
Feline infectious peritonitis (FIP) is a fatal disease caused by mutations in feline enteric coronavirus, posing significant challenges in feline medicine. GS-441524 (GS), the active metabolite of remdesivir, has demonstrated efficacy in FIP treatment. However, its poor solubility and low oral bioavailability require high doses for therapeutic effect, limiting its practicality. This study aimed to overcome these limitations by transforming GS into hydrochloride (GS-H) and sulfate (GS-S) salts, substantially improving solubility and bioavailability. Among these, GS-S exhibited 58-fold higher solubility and 3.8-fold higher plasma concentration than GS, making it the preferred candidate for further development. To overcome challenges in feline oral drug administration, GS-S-based orally disintegrating tablet (ODT) was developed to disintegrate rapidly in the feline oral cavity, ensuring easier administration and accurate dosing. The formulation, comprising mannitol, microcrystalline cellulose, crospovidone, and polyvinylpyrrolidone, disperses in water within 7.7 s, providing an alternative when direct oral administration is challenging. The GS-S-based ODT (GS-S ODT) maintained pharmacokinetic properties comparable to GS-S powder, confirming its potential as a practical alternative. This study explores advancements in GS formulation by integrating enhanced bioavailability with improved administration convenience, providing a foundation for more effective and accessible FIP treatments to address key challenges in feline healthcare.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40789473/